NO20074404L - Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid - Google Patents

Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid

Info

Publication number
NO20074404L
NO20074404L NO20074404A NO20074404A NO20074404L NO 20074404 L NO20074404 L NO 20074404L NO 20074404 A NO20074404 A NO 20074404A NO 20074404 A NO20074404 A NO 20074404A NO 20074404 L NO20074404 L NO 20074404L
Authority
NO
Norway
Prior art keywords
microcrystalline
quinolin
indol
ylmethyl
fluoro
Prior art date
Application number
NO20074404A
Other languages
English (en)
Norwegian (no)
Inventor
Edward Andrew Boyd
Frederick Arthur Brookfield
Christopher James Brennan
Christopher Francis Palmer
Leigh Pearcey
James Matthew Lovell
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Publication of NO20074404L publication Critical patent/NO20074404L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074404A 2005-03-01 2007-08-29 Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid NO20074404L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504150.4A GB0504150D0 (en) 2005-03-01 2005-03-01 Microcrystalline material
PCT/GB2006/000704 WO2006092579A1 (en) 2005-03-01 2006-03-01 Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid

Publications (1)

Publication Number Publication Date
NO20074404L true NO20074404L (no) 2007-10-25

Family

ID=34430394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074404A NO20074404L (no) 2005-03-01 2007-08-29 Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid

Country Status (16)

Country Link
US (1) US20100041699A1 (ja)
EP (1) EP1856094A1 (ja)
JP (1) JP2008531668A (ja)
KR (1) KR20070107184A (ja)
CN (1) CN101133047A (ja)
AU (1) AU2006219689A1 (ja)
BR (1) BRPI0607423A2 (ja)
CA (1) CA2600891A1 (ja)
GB (1) GB0504150D0 (ja)
IL (1) IL185453A0 (ja)
MX (1) MX2007010588A (ja)
NO (1) NO20074404L (ja)
NZ (1) NZ561246A (ja)
RU (1) RU2007132203A (ja)
WO (1) WO2006092579A1 (ja)
ZA (1) ZA200707233B (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
EP2051962B1 (en) 2006-08-07 2011-10-26 Actelion Pharmaceuticals Ltd. (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
WO2009061730A2 (en) 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US8470594B2 (en) * 2008-04-15 2013-06-25 President And Fellows Of Harvard College Methods for identifying agents that affect the survival of motor neurons
US9180114B2 (en) 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
JP5069804B2 (ja) * 2010-03-01 2012-11-07 隆雄 篠澤 筋萎縮性側索硬化症(als)の患者の進行度を判定し進行のモニターを行う方法
PL2558447T3 (pl) 2010-03-22 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
WO2020136095A1 (en) 2018-12-27 2020-07-02 Chiesi Farmaceutici S.P.A. Pharmaceutical composition comprising spherical agglomerates of timapiprant
CN113975272A (zh) * 2021-11-29 2022-01-28 西安交通大学 吲哚乙酸(iaa)在制备预防或治疗炎症性肠病药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy

Also Published As

Publication number Publication date
NZ561246A (en) 2009-09-25
CN101133047A (zh) 2008-02-27
US20100041699A1 (en) 2010-02-18
JP2008531668A (ja) 2008-08-14
WO2006092579A1 (en) 2006-09-08
RU2007132203A (ru) 2009-04-10
EP1856094A1 (en) 2007-11-21
AU2006219689A2 (en) 2006-09-08
BRPI0607423A2 (pt) 2016-11-08
GB0504150D0 (en) 2005-04-06
MX2007010588A (es) 2007-10-23
CA2600891A1 (en) 2006-09-08
KR20070107184A (ko) 2007-11-06
AU2006219689A1 (en) 2006-09-08
ZA200707233B (en) 2008-11-26
IL185453A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
NO20074404L (no) Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
EA200801381A1 (ru) Производные пиримидина
TNSN07463A1 (en) Process for the synthesis of organic compounds
NO20053340D0 (no) Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1).
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
MX2009004154A (es) Purinas como inhibidores de pkc-theta.
NO20070379L (no) Kjemiske forbindelser
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
CL2012000114A1 (es) Proceso para la preparacion de compuestos derivados de 5-amino-benzonorbornadieno donde se hacer reaccionar un compuesto de 5-halo-benzonorbornadieno con una bencilamina en prensecia de un catalizador de paladio.
NO20070564L (no) Kinoliner uten tiazolinonsubstituenter.
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
NO20061622L (no) Ekspansjonskloanordning for en innfelt installasjonsenhet
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
NO20075618L (no) Novel compounds as GLP-1 Agonists
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
HUP0401486A2 (hu) Eljárás piridinvegyületek előállítására
AR064306A1 (es) Antagonistas del receptor de angiotensina ii
NO20072551L (no) Fremgangsmate for fremstilling av purinforbindelser
NO20074101L (no) Isolering av CCI-779 fra morvaesker
WO2007085651A8 (en) Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds
DE602007009367D1 (de) Yl)-n-methylbenzylamin
DK1807401T3 (da) Fremgangsmåde til fremstilling af phenyl-2-pyrimidinylketoner samt deres nye mellemprodukter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application